PDF(Pubmed)
Abstract：
UNASSIGNED: Uterine leiomyomas, or fibroids, are prevalent benign gynecological tumors affecting many women during their reproductive years. While surgical excision has long been the gold standard for fibroid treatment, the pharmacological management, including progesterone receptor modulators like mifepristone (RU 486), has garnered attention due to the reduced surgical approaches. However, there is a notable paucity of research on the effectiveness of mifepristone, on the same. This study seeks to evaluate the safety and efficacy of mifepristone in reducing uterine leiomyoma size and alleviating associated symptoms.
UNASSIGNED: Conducted prospectively, the study enrolled 20 pre-menopausal women, aged 18 years or older, from Nanavati Max Super Speciality Hospital Mumbai, Maharashtra, India. Participants were selected based on specific inclusion criteria, including the presence of at least one uterine myoma with a minimum diameter of 2.5 cm as confirmed by ultrasound. Participants had an average age of 39.75 years and an average BMI of 27.58 kg/m2.
UNASSIGNED: The study found that mifepristone significantly reduced uterine volume by 75%, with hemoglobin levels substantially improving from 9 gm/dL initially to 12.51 gm/dL after six months. Pain intensity, assessed using the Visual Analog Scale (VAS) score, gradually decreased from baseline to three-month, with all 20 patients reporting the complete absence of pelvic pain by six months.
UNASSIGNED: This prospective study highlights mifepristone\'s promise as a non-surgical approach to effectively reduce uterine fibroid volume, improve hemoglobin levels, and mitigate uterine blood loss in patients.
UNASSIGNED: Conducted prospectively, the study enrolled 20 pre-menopausal women, aged 18 years or older, from Nanavati Max Super Speciality Hospital Mumbai, Maharashtra, India. Participants were selected based on specific inclusion criteria, including the presence of at least one uterine myoma with a minimum diameter of 2.5 cm as confirmed by ultrasound. Participants had an average age of 39.75 years and an average BMI of 27.58 kg/m2.
UNASSIGNED: The study found that mifepristone significantly reduced uterine volume by 75%, with hemoglobin levels substantially improving from 9 gm/dL initially to 12.51 gm/dL after six months. Pain intensity, assessed using the Visual Analog Scale (VAS) score, gradually decreased from baseline to three-month, with all 20 patients reporting the complete absence of pelvic pain by six months.
UNASSIGNED: This prospective study highlights mifepristone\'s promise as a non-surgical approach to effectively reduce uterine fibroid volume, improve hemoglobin levels, and mitigate uterine blood loss in patients.
摘要：
■子宫平滑肌瘤，或肌瘤，是常见的良性妇科肿瘤，影响许多妇女在生育年龄。虽然手术切除长期以来一直是纤维瘤治疗的金标准，药理学管理，包括孕激素受体调节剂，如米非司酮（RU486），由于手术方法的减少，引起了人们的注意。然而,关于米非司酮有效性的研究明显缺乏，在相同的。这项研究旨在评估米非司酮在减少子宫平滑肌瘤大小和减轻相关症状方面的安全性和有效性。
■前瞻性地进行，这项研究招募了20名绝经前妇女，18岁或以上，孟买纳纳瓦蒂·马克斯超级专科医院，马哈拉施特拉邦,印度。参与者是根据具体的入选标准选择的，包括超声证实的至少一个最小直径为2.5厘米的子宫肌瘤的存在。参与者的平均年龄为39.75岁，平均BMI为27.58kg/m2。
■研究发现米非司酮使子宫体积显著减少75%,血红蛋白水平从最初的9gm/dL大幅改善至6个月后的12.51gm/dL。疼痛强度,使用视觉模拟量表(VAS)评分进行评估，从基线逐渐下降到三个月，所有20例患者报告到6个月时完全没有盆腔疼痛。
这项前瞻性研究强调了米非司酮作为有效减少子宫肌瘤体积的非手术方法的承诺，提高血红蛋白水平，减轻患者的子宫失血。
■前瞻性地进行，这项研究招募了20名绝经前妇女，18岁或以上，孟买纳纳瓦蒂·马克斯超级专科医院，马哈拉施特拉邦,印度。参与者是根据具体的入选标准选择的，包括超声证实的至少一个最小直径为2.5厘米的子宫肌瘤的存在。参与者的平均年龄为39.75岁，平均BMI为27.58kg/m2。
■研究发现米非司酮使子宫体积显著减少75%,血红蛋白水平从最初的9gm/dL大幅改善至6个月后的12.51gm/dL。疼痛强度,使用视觉模拟量表(VAS)评分进行评估，从基线逐渐下降到三个月，所有20例患者报告到6个月时完全没有盆腔疼痛。
这项前瞻性研究强调了米非司酮作为有效减少子宫肌瘤体积的非手术方法的承诺，提高血红蛋白水平，减轻患者的子宫失血。
